Localised and unresectable neuroblastoma in infants: Excellent outcome with primary chemotherapy
| Autor: | Dominique Plantaz, Marie Cecile Peyroulet, Pascal Chastagner, Marie Christine Baranzelli, Carole Coze, Didier Frappaz, Jean Michon, Hervé Rubie |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Response rate (survey)
Cancer Research Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Intensive chemotherapy medicine.disease Surgery medicine.anatomical_structure Oncology Neuroblastoma Pediatrics Perinatology and Child Health medicine Overall survival Primary chemotherapy Surgical excision Bone marrow business |
| Zdroj: | Medical and Pediatric Oncology. 36:247-250 |
| ISSN: | 1096-911X 0098-1532 |
| Popis: | Procedure Infants with neuroblastoma (NB) were assessed according to INSS recommendations, including MIBG scan and extensive bone marrow staging to eliminate metastatic spread. Patients with unresectable tumour received chemotherapy, including two courses of carboplatin-etoposide (CE) and two of vincristine-cyclophosphamide-doxorubicin (CAdO). Post-operative treatment was to be given only in infants with MYCN amplification. Between 1990 and 1994, 52 consecutive children were registered. Results Among the 44 patients who received CE as a first course, the response rate was 66% and the primary could be removed in all children but one, who was in remission. The toxicity was mainly haematological and was always manageable. The 5 year overall survival (OS) and event-free survival (EFS) were 94 and 90 ± 8%, respectively, with a median follow-up of 48 months. The outcome of infants with no MYCN amplification was excellent; OS and EFS were, respectively, 97 and 94%. Conclusions Chemotherapy allows surgical excision and excellent outcome in infants with localised and unresectable NB. Less intensive Chemotherapy should be investigated in such patients. Med. Pediatr. Oncol. 36:247–250, 2001.© 2001 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text